Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany

NCT00357097 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00357097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00357097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
December 31, 2007
Enrollment
240 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe idiopathic restless legs syndrome (rls), restless legs syndrome